NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it will acquire electron microscopy firm FEI Company for $4.2 billion in cash, or $107.50 per share.

Thermo Fisher President and CEO Marc Casper said in a statement that his company will use FEI's technology to complement its existing mass spectrometry business, particularly in its work on structural proteins and biopharmaceuticals.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.